Single domain antibody: Development and application in biotechnology and biopharma
2024
Single Domain Antibodies: Development and Applications
publication
Evidence: high
Author Information
Author(s): Yu Ting, Zheng Fang, He Wenbo, Muyldermans Serge, Wen Yurong
Primary Institution: Xi'an Jiaotong University
Hypothesis
The evolutionary history and applications of heavy-chain antibodies (HCAbs) in biotechnology and pharmaceuticals.
Conclusion
Nanobodies, derived from HCAbs, have significant potential in diagnostics and therapeutics due to their unique properties.
Supporting Evidence
- Nanobodies are effective in targeting specific antigens in cancer therapy.
- Nanobodies can cross the blood-brain barrier, making them useful for neurological disorders.
- Commercial nanobody drugs have been developed and are in use, indicating their practical applications.
Takeaway
Nanobodies are tiny antibodies that can help doctors find and treat diseases better because they are small and can easily get into places regular antibodies can't.
Methodology
The review discusses the evolutionary origins of HCAbs and their applications in various medical fields, including cancer treatment and diagnostics.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website